Patent · US Active

CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker

US12006339B2 · kind B2 · utility

0Cited by
3References
31Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 19, 2023
Grant dateJun 11, 2024
Priority date
Expiry dateMay 19, 2043

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07F9/65397
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are novel compounds containing a polymeric carbohydrate backbone, one or more mannose-binding C-type lectin receptor targeting moieties, and a nitrogenous bisphosphonate compound coupled to the backbone via a thiol-maleimide conjugation, in addition to pharmaceutical compositions, methods of synthesizing, and methods of use. The thiol-maleimide conjugation of a bisphosphonate to a polymeric carbohydrate backbone provides for methods of using the compounds and compositions thereof for releasing the therapeutic payload when internalized into a mannose-binding C-type lectin receptor-expressing cell, such as tumor associated macrophages (TAMs) for the treatment of various diseases, including, cancer, autoimmune diseases, and inflammatory disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.